Treatment of ocular myasthenia gravis

Current Treatment Options in Neurology

Volumn 14, Issue 1, 2012, Pages 103-112

  Haines, Scott R ^a   Thurtell, Matthew J ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Acetylcholinesterase inhibitors; Contact lenses; Diplopia; Ocular myasthenia gravis; Prednisone; Ptosis; Pyridostigmine; Steroid sparing agents; Steroids; Surgery; Thymectomy; Treatment

Indexed keywords

ALLOPURINOL; ANTISENSE OLIGONUCLEOTIDE; ATROPINE PLUS DIPHENOXYLATE; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MONARSEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPHAZOLINE; NEOSTIGMINE; OPIATE; PREDNISONE; PYRIDOSTIGMINE; RITUXIMAB; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; WARFARIN;

ABDOMINAL CRAMP; ADRENAL INSUFFICIENCY; ANTISENSE THERAPY; ARTICLE; AVASCULAR NECROSIS; BONE MARROW SUPPRESSION; BONE NECROSIS; BRADYCARDIA; CENTRAL NERVOUS SYSTEM DEPRESSION; CONGESTIVE HEART FAILURE; CONSERVATIVE TREATMENT; CONTACT LENS; CORTICOSTEROID INDUCED OSTEOPOROSIS; CUSHING SYNDROME; DEVICES; DIABETES MELLITUS; DIARRHEA; DIGESTIVE SYSTEM ULCER; DIPLOPIA; DISEASE CONTROL; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG MEGADOSE; EYE DISEASE; EYE SURGERY; EYELID ELEVATION SURGERY; EYELID SUPPORT; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GLAUCOMA; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; INFECTION; MAINTENANCE THERAPY; MORNING DOSAGE; MUSCLE CRAMP; MUSCLE TWITCH; MYASTHENIA GRAVIS; MYOPATHY; NAUSEA; OCCLUSIVE DEVICE; PLASMAPHERESIS; PRISM; PSYCHOSIS; PTOSIS; RETROSPECTIVE STUDY; SECRETION; SIDE EFFECT; STRABISMUS; STRABISMUS SURGERY; SWEATING; THYMECTOMY; THYMOMA; TREATMENT CONTRAINDICATION; TREATMENT DURATION;

EID: 84857626035     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-011-0151-8     Document Type: Article

References (32)

1. A Jani-Acsadi R Lisak 2010 Myasthenia gravis Curr Treat Options Neurol 12 231 243 20842584 10.1007/s11940-010-0070-0
2. J Pal C Rozsa S Komoly, et al. 2011 Clinical and biological heterogeneity of autoimmune myasthenia gravis J Neuroimmunol 231 43 54 21093931 10.1016/j.jneuroim.2010.10.020 1:CAS:528:DC%2BC3MXjtFertLs%3D This is an excellent review of the biologic basis of MG. There is a brief discussion of the unique immunologic properties of extraocular muscles.
3. U Luchanok H Kaminski 2008 Ocular myasthenia: diagnostic and treatment recommendations and the evidence base Curr Opin Neurol 21 8 15 18180646 10.1097/WCO.0b013e3282f4098e
4. N Porter B Salter 2005 Ocular myasthenia gravis Curr Treat Options Neurol 7 79 88 15610710 10.1007/s11940-005-0009-z (Pubitemid 40220522)
5. M Benatar 2006 A systematic review of diagnostic studies in myasthenia gravis Neuromuscul Disord 16 459 467 16793269 10.1016/j.nmd.2006.05.006 (Pubitemid 44094102)
6. N Miller J Morris M Maquire 1982 Combined use of neostigmine and ocular motility measurements in the diagnosis of myasthenia gravis Arch Ophthalmol 100 761 763 7082206 10.1001/archopht.1982.01030030765008 1:STN:280: DyaL383gsFGjtQ%3D%3D (Pubitemid 12156590)
7. V Zouvelou C Potagas N Karandreas, et al. 2008 Concurrent presentation of ocular myasthenia and euthyroid graves ophthalmopathy: a diagnostic challenge J Clin Neurosci 15 718 720 10.1016/j.jocn.2007.09.028
8. B Daroff 1986 The office tensilon test for ocular myasthenia gravis Arch Neurol 43 843 844 3729767 10.1001/archneur.1986.00520080081029 1:STN:280:DyaL283mvVCltA%3D%3D
9. MJ Kupersmith 2009 Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up J Neurol 256 1314 1320 19377863 10.1007/s00415-009-5120-8 This was a retrospective review of 87 patients with ocular MG treated with prednisone or with pyridostigmine only. The patients treated with prednisone showed a delayed onset and a reduced incidence of generalized MG.
10. M Gilbert E De Sousa P Savino 2007 Ocular myasthenia gravis treatment: the case against prednisone therapy and thymectomy Arch Neurol 64 1790 1792 18071047 10.1001/archneur.64.12.1790 (Pubitemid 350254946)
11. M Benatar H Kaminski 2007 Evidence report: the medical treatment of ocular myasthenia (an evidence review) Neurology 68 2144 2149 17460154 10.1212/01.wnl.0000263481.14289.90 (Pubitemid 46912135)
12. V Kumar H Kaminski 2011 Treatment of myasthenia gravis Curr Neurol Neurosci Rep 11 89 96 20927659 10.1007/s11910-010-0151-1 1:CAS:528: DC%2BC3MXjtVSgsA%3D%3D
13. M Mehndiratta S Pandey T Kuntzer 2011 Acetylcholinesterase inhibitor treatment for myasthenia gravis (review) Cochrane Libr 2 1 16
14. J Diaz-Manera R Rojas-Garcia I Illa 2009 Treatment strategies for myasthenia gravis Expert Opin Pharmacother 10 1329 1342 19445561 10.1517/14656560902950619 1:CAS:528:DC%2BD1MXmtlWqsrc%3D
15. J Finsterer M Frank E Krexner 2010 Low-dose azathioprine effectively suppresses clinical and immunological manifestations of generalized myasthenia South Med J 103 182 184 20065912 10.1097/SMJ.0b013e3181c81b93
16. G Skeie S Apostolski A Evoli, et al. 2010 Guidelines for treatment of autoimmune neuromuscular transmission disorders Eur J Neurol 17 893 902 20402760 10.1111/j.1468-1331.2010.03019.x 1:STN:280:DC%2BC3cnotFyhtw%3D%3D
17. Y Nagane K Utsugisawa S Suzuki, et al. 2011 Topical naphazoline in the treatment of myasthenic blepharoptosis Muscle Nerve 44 41 44 21491460 10.1002/mus.22002 1:CAS:528:DC%2BC3MXntlOrtbY%3D
18. A Antonio-Santos E Eggenberger 2008 Medical treatment options for ocular myasthenia gravis Curr Opin Ophthalmol 19 468 478 18854691 10.1097/ICU. 0b013e328310da18
19. I Cortese V Chaudry Y So, et al. 2011 Evidence based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology 76 294 300 21242498 10.1212/WNL.0b013e318207b1f6 1:CAS:528: DC%2BC3MXnsFSnsA%3D%3D
20. H Ibrahim M Dimachkie A Shaibani 2010 A review: the uses of rituximab in neuromuscular diseases J Clin Neuromuscul Dis 12 91 102 21386778 10.1097/CND.0b013e3181ff49f3
21. A Mandawat H Kaminski G Cutter, et al. 2010 Comparative analysis of therapeutic options used for myasthenia gravis Ann Neurol 68 797 805 21061395 10.1002/ana.22139
22. C Angelini 2011 Diagnosis and management of autoimmune myasthenia gravis Clin Drug Investig 31 1 14 21053987 1:CAS:528:DC%2BC3MXmt1aq
23. M Zielinksi 2011 Management of myasthenic patients with thymoma Thorac Surg Clin 21 47 57 10.1016/j.thorsurg.2010.08.009
24. Z Chen H Luo Y Peng, et al. 2011 Comparative clinical features and immune responses after extended thymectomy for myasthenia gravis in patients with atrophic versus hyperplastic thymus Ann Thorac Surg 91 212 218 21172515 10.1016/j.athoracsur.2010.08.041
25. OC Morris J O'Day 2004 Strabismus surgery in the management of diplopia caused by myasthenia gravis Br J Ophthalmol 88 832 15148221 1:STN:280: DC%2BD2c3kvFKrtw%3D%3D (Pubitemid 38725597)
26. E Bradley G Bartley K Chapman, et al. 2001 Surgical correction of blepharoptosis in patients with myasthenia gravis Ophthal Plast Reconstr Surg 17 103 110 11281581 10.1097/00002341-200103000-00005 1:STN:280: DC%2BD3MvgvFeitw%3D%3D (Pubitemid 32220959)
27. B Evans 2006 Orthoptic indications for contact lens wear Cont Lens Anterior Eye 29 175 181 16713327 10.1016/j.clae.2006.03.007 (Pubitemid 44309425)
28. M Migneco 2008 Alleviating vertical diplopia through contact lenses without the use of prism Eye Contact Lens 34 297 298 18779671 10.1097/ICL.0b013e31817e7d95
29. Y Nagane S Suzuki N Suzuki, et al. 2011 Early aggressive treatment strategy against myasthenia gravis Eur Neurol 65 16 22 21116111 10.1159/000322497
30. J Sussman Z Argov D McKee, et al. 2008 Antisense treatment for myasthenia gravis: experience with monarsen Ann NY Acad Sci 1132 283 290 18567879 10.1196/annals.1405.022 1:CAS:528:DC%2BD1cXoslSksL8%3D (Pubitemid 351841365)
31. I Hennessey A Long I Hughes, et al. 2011 Thymectomy for inducing remission in juvenile myasthenia gravis Pediatr Surg Int 27 591 594 21243366 10.1007/s00383-010-2837-5
32. S Pineles R Avery H Moss, et al. 2010 Visual and systemic outcomes in pediatric ocular myasthenia gravis Am J Ophthalmol 15 453 459 10.1016/j.ajo.2010.05.002